Literature DB >> 175977

Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays.

M D Curry, P Alaupovic, C A Suenram.   

Abstract

Electroimmunoassays ("rocket" electrophoresis) are described for human serum apolipoprotein A and its constitutive A-I and A-II polypeptides. Purified lipoprotein A, A-I, and A-II were used to prepare monospecific antisera and to standardize assays. These specific, rapid (5-8 h), precise (the within-and between-assay coefficients of variations are 5 and 7%, respectively), and accurate (by gravimetry) assays are applicable to measurement of these polypeptides in whole serum and in various density classes of lipoproteins. Comparable results are obtained with intact and delipidized lipoproteins. Results correlated well with those obtained by radial immunodiffusion or radioimmunoassay. However, the present procedure is more rapid than the former and simpler than the latter immunoassay. Concentrations of A-I and A-II in the serum of normal men and women were similar (143 +/- 24 and 146 +/- 78 mg/dl, respectively, for A-I and 78 +/- 17 and 83 +/- 25 mg/dl for A-II). Subjects with type lla, llb, and IV hyperlipoproteinemias had similar concentrations of both polypeptides, while patients with type I disease, lecithin:cholesterol acyltransferase deficiency and LP-A deficiency had lowest concentrations of A-I (0.3-30 mg/dl) and A-II (11-20 mg/dl). The molar ratio of A-I/A-II in the serum and high-density lipoproteins was close to unity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 175977

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  26 in total

1.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.

Authors:  S T Kunitake; M R Jarvis; R L Hamilton; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

2.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

3.  Evidence for the lipoprotein heterogeneity of human plasma high density lipoproteins isolated by three different procedures.

Authors:  A Suenram; W J McConathy; P Alaupovic
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

4.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

Review 5.  Plasma apolipoproteins and risk for age related maculopathy.

Authors:  N Dashti; G McGwin; C Owsley; C A Curcio
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

6.  The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins.

Authors:  G Assmann; E Smootz; K Adler; A Capurso; K Oette
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

7.  Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I.

Authors:  J P McVicar; S T Kunitake; R L Hamilton; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.

Authors:  C N Corder; M R Goldberg; P A Alaupovic; M D Price; S S Furste
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Alpha- and gamma-tocopherol levels in lipoproteins fractionated by affinity chromatography.

Authors:  B A Clevidence; J Lehmann
Journal:  Lipids       Date:  1989-02       Impact factor: 1.880

10.  The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay.

Authors:  M C Cheung; J J Albers
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.